WO2003084469A3 - Tissue-specific endothelial membrane proteins - Google Patents
Tissue-specific endothelial membrane proteins Download PDFInfo
- Publication number
- WO2003084469A3 WO2003084469A3 PCT/US2003/010195 US0310195W WO03084469A3 WO 2003084469 A3 WO2003084469 A3 WO 2003084469A3 US 0310195 W US0310195 W US 0310195W WO 03084469 A3 WO03084469 A3 WO 03084469A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue
- specific
- ligand
- therapeutic moiety
- linker
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003222185A AU2003222185A1 (en) | 2002-04-01 | 2003-03-31 | Tissue-specific endothelial membrane proteins |
CA002481334A CA2481334A1 (en) | 2002-04-01 | 2003-03-31 | Tissue-specific endothelial membrane proteins |
GB0423854A GB2403222A (en) | 2002-04-01 | 2003-03-31 | Tissue-specific endothelial membrane proteins |
US10/794,899 US20040146516A1 (en) | 1999-06-17 | 2004-03-05 | Lumen-exposed molecules and methods for targeted delivery |
GBGB0424024.8A GB0424024D0 (en) | 2002-04-01 | 2004-10-29 | Tissue-specific endothelial membrane proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36945202P | 2002-04-01 | 2002-04-01 | |
US60/369,452 | 2002-04-01 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/794,899 Continuation-In-Part US20040146516A1 (en) | 1999-06-17 | 2004-03-05 | Lumen-exposed molecules and methods for targeted delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003084469A2 WO2003084469A2 (en) | 2003-10-16 |
WO2003084469A3 true WO2003084469A3 (en) | 2004-06-10 |
Family
ID=28791952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/010195 WO2003084469A2 (en) | 1999-06-17 | 2003-03-31 | Tissue-specific endothelial membrane proteins |
Country Status (4)
Country | Link |
---|---|
AU (1) | AU2003222185A1 (en) |
CA (1) | CA2481334A1 (en) |
GB (2) | GB2403222A (en) |
WO (1) | WO2003084469A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3101034A1 (en) | 2004-02-12 | 2016-12-07 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
FR2883873B1 (en) | 2005-03-31 | 2009-07-10 | Pharmamens Sarl | AGE INHIBITORS |
US20060239910A1 (en) | 2005-04-22 | 2006-10-26 | Morphotek Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
EP2434288B1 (en) | 2006-09-25 | 2014-07-30 | Universiteit Maastricht | Means and methods for diagnosing and/or treating a subject at risk of developing heart failure |
FI20075278A0 (en) * | 2007-04-20 | 2007-04-20 | Biotie Therapies Corp | Novel completely human anti-VAP-1 monoclonal antibodies |
ES2642516T3 (en) | 2007-09-04 | 2017-11-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Deletions in domain II of Pseudomonas exotoxin A that reduce non-specific toxicity |
EP3052483B1 (en) | 2013-10-01 | 2019-02-06 | GlaxoSmithKline Intellectual Property Development Limited | Compounds for affinity chromatography |
CN112535726B (en) * | 2019-09-05 | 2023-09-12 | 南京安吉生物科技有限公司 | Tumor marker AQUAPRIN 2 protein and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994002178A1 (en) * | 1992-07-27 | 1994-02-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting of liposomes to the blood-brain barrier |
US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US20030082176A1 (en) * | 2001-04-30 | 2003-05-01 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
-
2003
- 2003-03-31 AU AU2003222185A patent/AU2003222185A1/en not_active Abandoned
- 2003-03-31 WO PCT/US2003/010195 patent/WO2003084469A2/en not_active Application Discontinuation
- 2003-03-31 CA CA002481334A patent/CA2481334A1/en not_active Abandoned
- 2003-03-31 GB GB0423854A patent/GB2403222A/en not_active Withdrawn
-
2004
- 2004-10-29 GB GBGB0424024.8A patent/GB0424024D0/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
WO1994002178A1 (en) * | 1992-07-27 | 1994-02-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting of liposomes to the blood-brain barrier |
US20030082176A1 (en) * | 2001-04-30 | 2003-05-01 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
Non-Patent Citations (1)
Title |
---|
FISHER R.S. ET AL.: "Potential new methods for antiepileptic drug delivery", CNS DRUGS, vol. 16, no. 9, 2002, pages 579 - 593, XP002972018 * |
Also Published As
Publication number | Publication date |
---|---|
GB0423854D0 (en) | 2004-12-01 |
GB0424024D0 (en) | 2004-12-01 |
WO2003084469A2 (en) | 2003-10-16 |
AU2003222185A1 (en) | 2003-10-20 |
CA2481334A1 (en) | 2003-10-16 |
GB2403222A (en) | 2004-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002100336A3 (en) | Tissue-specific endothelial membrane proteins | |
Liu et al. | Prostate-specific membrane antigen directed selective thrombotic infarction of tumors | |
Crisp et al. | Dual targeting of integrin αvβ3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery | |
Böhme et al. | Drug delivery and release systems for targeted tumor therapy | |
Paranjpe et al. | Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation | |
ES2364452T3 (en) | METHOD FOR DESIGNING PROFESSIONAL COMPOUNDS ACTIVATED BY CD10. | |
WO2005082023A3 (en) | Heterocyclic self-immolative linkers and conjugates | |
CN101946001A (en) | Polypeptide-nucleic acid conjugates and uses thereof | |
AU2002337954B2 (en) | Integrin targeting compounds | |
WO1998051325A3 (en) | Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods | |
WO2004074434A3 (en) | Methods and compositions for administering therapeutic and diagnostic agents | |
WO2007018431A3 (en) | Triazole-containing releasable linkers and conjugates comprising the same | |
WO2002036161A3 (en) | Novel targeted compositions for diagnostic and therapeutic use | |
WO2008073162A3 (en) | Lysine acetylation sites | |
WO2002087510A3 (en) | Subcellular targeting of therapeutic proteins | |
WO2008079973A3 (en) | Egfr binding peptides and uses thereof | |
WO2005054279A8 (en) | Delivery peptides, their constructs with active agents and use | |
WO2002014500A3 (en) | Human genes and gene expression products | |
Chen et al. | Discovery of Peptide ligands for hepatic stellate cells using phage display | |
WO2001066753A3 (en) | Human genes and gene expression products | |
WO2005035550A3 (en) | Dual phase-pna conjugates for the delivery of pna through the blood brain barrier | |
WO2001077145A3 (en) | Integrin binding peptide derivatives | |
Wang et al. | A novel enediyne‐integrated antibody–drug conjugate shows promising antitumor efficacy against CD30+ lymphomas | |
WO2003084470A3 (en) | Compositions and methods for targeted biological delivery of molecular carriers | |
WO1999048536A3 (en) | Delivery of long lasting therapeutic agents by forming covalent attachments in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 0423854 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20030331 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2481334 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003222185 Country of ref document: AU |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |